APOA1 and Hepatic fibrosis: This sensitive, preclinical decline—occurring before conventional liver function abnormalities—underscores apolipoprotein A1 (Apo-A1)’s distinct utility as an early warning biomarker for hepatic fibrosis and its potential role in disease stratification.